{
  "docId": "019de073-e8d5-735f-8ffd-8a5102406a96",
  "docSlug": "3003a94fa3be7c8f2ff0fbac5a54b26e",
  "documentTitle": "Arbutus Biopharma | Results Presentation Deck | 15 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 15,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide outlines a clinical trial design with three arms and a follow-up period, followed by a summary of findings.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-e8d5-735f-8ffd-8a5102406a96/9",
  "deckHref": "/decks/019de073-e8d5-735f-8ffd-8a5102406a96",
  "deckJsonHref": "/decks/019de073-e8d5-735f-8ffd-8a5102406a96.json",
  "deckAnchorHref": "/decks/019de073-e8d5-735f-8ffd-8a5102406a96#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.6,
        "x": 0.35,
        "y": 0.14
      },
      "kind": "diagram",
      "text": "Study design timeline showing three treatment arms (AB-729+VBR+NA, AB-729+NA, VBR+NA) from baseline to week 48, followed by a 24-week follow-up.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d49f4ae4-f24d-4958-8c1c-47ce542b0514",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.3,
        "y": 0.7
      },
      "kind": "list",
      "text": "Preliminary results: Adding VBR to AB-729+NA: Does not result in greater on-treatment improvements in HBV biomarkers as compared to AB-729+NA alone. Does not have a negative impact on reducing sAg.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc177a1b-e505-476d-a37e-6d29685e70a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.65,
        "x": 0.3,
        "y": 0.53
      },
      "kind": "paragraph",
      "text": "Primary objective: evaluate safety and tolerability of vebicorvir (VBR) in combination with AB-729 in patients with cHBV receiving NA therapy. n= 65 virologically-suppressed patients with cHBV infection.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1fd9187-70d4-4a2d-ade3-de0f57379b03",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.24,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "title",
      "text": "AB-729 Clinical Collaboration",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee1a1c75-b555-4e06-a555-9a6e7932492d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Three-Act Structure",
      "slug": "three-act-structure",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "5551628e-7953-47fd-a11d-a4fe24f4be5b",
      "evidence": "Primary objective: evaluate safety and tolerability of vebicorvir (VBR) in combination with AB-729 in patients with cHBV receiving NA therapy.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}